Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remygen in Type 1 Diabetes
NCT03635437Phase 2Completed
- Sponsor
- Per-Ola Carlsson
- Start
- Sep 2018
- Primary completion
- Sep 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Targeted Protein Degraders (TPDs), Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of remygen in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Per-Ola Carlsson. Primary endpoint: Adverse events possibly or probably related to GABA treatment at 6 months. Started Sep 2018; status: completed.
02
Drugs
remygen
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03635437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635437.